Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 154-165

  Russo, Ethan B ^a  

^a PHYTECS   (United States)

Author keywords

anandamide; anorexia nervosa; cannabidiol; cannabinoids; depression; endocannabinoids; fibromyalgia; Huntington disease; irritable bowel syndrome; migraine; motion sickness; multiple sclerosis; Parkinson disease; post traumatic stress disorder; prebiotics; THC

Indexed keywords

ENDOCANNABINOID;

CLINICAL FEATURE; CLINICAL STUDY; COMORBIDITY; DATA BASE; DISEASE ASSOCIATION; FIBROMYALGIA; HUMAN; IRRITABLE COLON; MICROBIOME; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84991754888     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2016.0009     Document Type: Review

References (99)

1. Russo EB. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther. 2001;1:21-92.
2. Russo EB. Handbook of psychotropic herbs: a scientific analysis of herbal remedies for psychiatric conditions. Haworth Press: Binghamton, NY, 2001.
3. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett. 2004;25:31-39.
4. McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9:e89566.
5. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 2013;280:1918-1943.
6. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. In: Recent Advances in Tryptophan Research (Filippini GA, ed). Plenum Press: New York, 1996, pp. 373-379.
7. Peres MF, Young WB, Kaup AO, et al. Fibromyalgia is common in patients with transformed migraine. Neurology. 2001;57:1326-1328.
8. Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3541-3546.
9. Fride E, Bregman T, Kirkham TC. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood). 2005;230:225-234.
10. Fride E. Cannabinoids and cystic fibrosis: a novel approach. J Cannabis Ther. 2002;2:59-71.
11. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ''N of 1'' studies. Anaesthesia. 2004;59:440-452.
12. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.
13. Jarvinen T, Pate D, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther. 2002;95:203-220.
14. Russo E. Cannabis treatments in obstetrics and gynecology: a historical review. J Cannabis Ther. 2002;2:5-35.
15. Westfall R, Janssen P, Lucas P, et al. Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of tis efficacy against 'morning sickness'. Complement Ther Clin Pract. 2006;12:27-33.
16. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530-534.
17. Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005;435:1108-1112.
18. Ashton CH, Moore PB, Gallagher P, et al. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 2005;19:293-300.
19. Clarke G, Cryan JF, Dinan TG, et al. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther. 2012;35:403-413.
20. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol. 2001;429:177-193.
21. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut. 2001;48:859-867.
22. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs. 2003;12:39-49.
23. O'Shaughnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica); their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Trans Med Phys Soc Bengal. 1838-1840;71-102:421-461.
24. Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology. 2003;125:765-774.
25. Smid SD, Bjorklund CK, Svensson KM, et al. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. Eur J Pharmacol. 2007;575:168-176.
26. Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923-929.
27. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845-852.
28. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
29. Wong BS, Camilleri M, Eckert D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012;24:358-e169.
30. Camilleri M, Kolar GJ, Vazquez-Roque MI, et al. Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am J Physiol Gastrointest Liver Physiol. 2013;304:G553-G560.
31. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59:291-295.
32. Esfandyari T, Camilleri M, Busciglio I, et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol. 2007;293:G137-G145.
33. Klooker TK, Leliefeld KE, Van Den Wijngaard RM, et al. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil. 2011;23:30-35, e2.
34. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35-37.
35. Cluny NL, Keenan CM, Reimer RA, et al. Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with delta9-tetrahydrocannabinol. PLoS One. 2015;10:e0144270.
36. Capasso R, Orlando P, Pagano E, et al. Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB(1) receptors and TRPV1 channels. Br J Pharmacol. 2014;171:4026-4037.
37. Underwood E. A shot at migraine. Science. 2016;351:116-119.
38. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76:3-8.
39. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been. Headache. 2015;55:885-916.
40. Greco R, Gasperi V, Maccarrone M, et al. The endocannabinoid system and migraine. Exp Neurol. 2010;224:85-91.
41. Boger DL, Patterson JE, Jin Q. Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide. Proc Natl Acad Sci U S A. 1998;95:4102-4107.
42. Walker JM, Hohmann AG, Martin WJ, et al. The neurobiology of cannabinoid analgesia. Life Sci. 1999;65:665-673.
43. Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2003;309:56-63.
44. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol. 2004;142:1354-1360.
45. Fusco BM, Barzoi G, Agro F. Repeated intranasal capsaicin applications to treat chronic migraine. Br J Anaesth. 2003;90:812.
46. Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007;320:64-71.
47. Greco R, Mangione AS, Sandrini G, et al. Effects of anandamide in migraine: data from an animal model. J Headache Pain. 2011.
48. Cupini LM, Bari M, Battista N, et al. Abnormal degradation of endocannabinoids in migrainous women. Cephalalgia. 2003;23:684.
49. Cupini LM, Costa C, Sarchielli P, et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008;30:186-189.
50. Rossi C, Pini LA, Cupini ML, et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol. 2008;64:1-8.
51. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007;32:1384-1390.
52. Kazemi H, Rahgozar M, Speckmann EJ, et al. Effect of cannabinoid receptor activation on spreading depression. Iran J Basic Med Sci. 2012;15:926-936.
53. Perrotta A, Arce-Leal N, Tassorelli C, et al. Acute reduction of anandamidehydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 2012;52:1350-1361.
54. Nozaki C, Markert A, Zimmer A. Inhibition of FAAH reduces nitroglycerininduced migraine-like pain and trigeminal neuronal hyperactivity in mice. Eur Neuropsychopharmacol. 2015;25:1388-1396.
55. Juhasz G, Lazary J, Chase D, et al. Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett. 2009;461:116-120.
56. el-Mallakh RS. Marijuana and migraine. Headache. 1987;27:442-443.
57. Rhyne DN, Anderson SL, Gedde M, et al. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy. 2016;36:505-510.
58. Gowers WR. A lecture on lumbago: its lessons and analogues. Br Med J. 1904;1:117-121.
59. Caro XJ, Winter EF. The role and importance of small fiber neuropathy in fibromyalgia pain. Curr Pain Headache Rep. 2015;19:55.
60. Bennett RM. Rational management of fibromyalgia. Rheum Dis Clin North Am. 2002;28:xiii-xv.
61. Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am. 2002;28:181-199, v.
62. Nicolodi M, Volpe AR, Sicuteri F. Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: their common clues. Cephalalgia. 1998;18(Suppl 21): 41-44.
63. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci. 1998;18:451-457.
64. Schley M, Legler A, Skopp G, et al. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin. 2006;22:1269-1276.
65. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-173.
66. Ware MA, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110:604-610.
67. Fiz J, Duran M, Capella D, et al. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One. 2011;6:e18440.
68. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4:1729-1743.
69. Russo EB, Hohmann AG. Role of cannabinoids in pain management. In: Comprehensive Treatment of Chronic Pain by Medical, Interventional and Behavioral Approaches (Deer T, Gordin V, eds.). Springer: New York, 2013, pp. 181-197.
70. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210-220.
71. National Pain Report. Marijuana rated most effective for treating fibromyalgia. National Pain Report, 2014. Available at: http://nationalpainreport.com/marijuana-rated-most-effective-for-treating-fibromyalgia-8823638.html
72. Chouker A, Kaufmann I, Kreth S, et al. Motion sickness, stress and the endocannabinoid system. PLoS One. 2010;5:e10752.
73. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15:300-302.
74. Di Filippo M, Pini LA, Pelliccioli GP, et al. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:1224-1229.
75. Silva M, Martins D, Charrua A, et al. Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy. Neuropharmacology. 2016;107:49-57.
76. Bisogno T, Martire A, Petrosino S, et al. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem Int. 2008;52:307-313.
77. Allen KL, Waldvogel HJ, Glass M, et al. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat. 2009;37:266-281.
78. Van Laere K, Casteels C, Dhollander I, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010;51:1413-1417.
79. Pisani A, Fezza F, Galati S, et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol. 2005;57:777-779.
80. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445:643-647.
81. Bluett RJ, Gamble-George JC, Hermanson DJ, et al. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry. 2014;4:e408.
82. Heitland I, Klumpers F, Oosting RS, et al. Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. Transl Psychiatry. 2012;2:e162.
83. Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38:2952-2961.
84. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18: 1034-1040.
85. Neumeister A, Seidel J, Ragen BJ, et al. Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder. Psychoneuroendocrinology. 2015;51:577-584.
86. Gabbay FE, Choi KH, Wynn GH, et al. The role of endoncannbinoid function in posttraumatic stress disorder: modulation the risk phenotype and rendering effects of trauma. In: Cannabinoids in Neurologic and Mental Disease (Fattore L, ed.). Academic Press: London, 2015, pp. 247-288.
87. Morena M, Patel S, Bains JS, et al. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41:80-102.
88. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol. 2005;16:333-352.
89. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108-2114.
90. Gerard N, Pieters G, Goffin K, et al. Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry. 2011;70:777-784.
91. Gross H, Ebert MH, Faden VB, et al. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol. 1983;3:165-171.
92. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioidtreated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13:438-449.
93. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344-1364.
94. Russo EB, Mead AP, Sulak D. Current status and future of cannabis research. Clin Researcher. 2015:58-63.
95. Foldy C, Malenka RC, Sudhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78:498-509.
96. Anderson GR, Aoto J, Tabuchi K, et al. Beta-neurexins control neural circuits by regulating synaptic endocannabinoid signaling. Cell. 2015;162:593-606.
97. Pacher P, Kunos G. Cardiovascular, metabolic, liver kidney and inflammatory disorders. In: Handbook of Cannabis (Pertwee R, ed.). Oxford University Press: Oxford, United Kingdom, 2014, pp. 564-581.
98. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs. 1998;30:187-196.
99. Raichlen DA, Foster AD, Gerdeman GL, et al. Wired to run: exerciseinduced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. J Exp Biol. 2012;215:1331-1336.